CFT7455 exhibits favorable physiochemical properties, pharmacokinetic parameters, and good oral bioavailability in preclinical studies. CFT7455 is more potent and catalytically active than other approved IMiDs and is currently in multiple clinical trials for treatment of multiple myeloma and relapsed/refractory non-Hodgkin's lymphoma. 88 DKY709 (Table ) as a CRBN binder induces formation of the CRBN-DKY709-IKZF2 ternary complex. This ternary complex promotes ubiquitination and degradation of IKZF2. DKY709 in combination with spartalizumab, is currently in clinical trial in patients with advanced solid tumors including melanoma. 89